A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation

Trial Profile

A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs OPC 108459 (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms CADENCE-215
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 11 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 01 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 01 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top